Published in Breast Cancer (Dove Med Press) on March 10, 2010
The Microenvironmental Effect in the Progression, Metastasis, and Dormancy of Breast Cancer: A Model System within Bone Marrow. Int J Breast Cancer (2012) 0.86
Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance. Curr Neuropharmacol (2012) 0.83
Three interrelated themes in current breast cancer research: gene addiction, phenotypic plasticity, and cancer stem cells. Breast Cancer Res (2011) 0.81
Epithelial cell culture models for the prevention and therapy of clinical breast cancer (Review). Oncol Lett (2012) 0.80
A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer. J Biomol Screen (2012) 0.80
Links between cancer stem cells and epithelial-mesenchymal transition. Onco Targets Ther (2015) 0.79
Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer. Oncol Lett (2015) 0.79
CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy. BMC Cancer (2013) 0.79
Exposure of tumor-associated macrophages to apoptotic MCF-7 cells promotes breast cancer growth and metastasis. Int J Mol Sci (2015) 0.76
Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer. Biomed Rep (2017) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 12.96
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 8.33
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol (2002) 7.92
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A (2004) 6.84
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med (1997) 6.13
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res (2005) 5.87
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
Adenovirus serotype 5 hexon mediates liver gene transfer. Cell (2008) 5.00
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res (2004) 4.53
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24
The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood (2002) 4.02
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res (2008) 3.97
Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol (2004) 3.87
Myogenic specification of side population cells in skeletal muscle. J Cell Biol (2002) 3.74
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Breast cancer: origins and evolution. J Clin Invest (2007) 3.31
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene (2003) 3.12
Co-evolution of tumor cells and their microenvironment. Trends Genet (2008) 3.08
Rational targeting of Notch signaling in cancer. Oncogene (2008) 3.02
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res (2002) 2.75
Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A (2002) 2.74
Functional and molecular characterisation of mammary side population cells. Breast Cancer Res (2002) 2.63
The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia (2009) 2.60
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A (2008) 2.53
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med (2007) 2.29
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci (2000) 2.21
Molecular phenotype of airway side population cells. Am J Physiol Lung Cell Mol Physiol (2003) 2.20
Side population cells and Bcrp1 expression in lung. Am J Physiol Lung Cell Mol Physiol (2003) 1.90
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Kidney side population reveals multilineage potential and renal functional capacity but also cellular heterogeneity. J Am Soc Nephrol (2006) 1.70
Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter. Biochem Biophys Res Commun (2002) 1.67
Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene (2007) 1.67
Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia (2007) 1.62
Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp Cell Res (2004) 1.60
Demystifying SP cell purification: viability, yield, and phenotype are defined by isolation parameters. Exp Cell Res (2004) 1.60
From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets (2007) 1.58
Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am J Pathol (2003) 1.49
A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res (2008) 1.48
Identification and targeting of cancer stem cells. Bioessays (2009) 1.44
Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat (2008) 1.41
Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer (2009) 1.40
Retinoids in chemoprevention and differentiation therapy. Carcinogenesis (2000) 1.38
MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest (2009) 1.38
Phenotype and hematopoietic potential of side population cells throughout embryonic development. Blood (2003) 1.38
Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol (2009) 1.32
Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res (2008) 1.30
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat (2009) 1.29
Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis (2009) 1.29
Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther (2009) 1.27
MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. Med Oncol (2009) 1.26
Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol Cell Biochem (2007) 1.25
Side population cells in human and mouse epidermis lack stem cell characteristics. Exp Cell Res (2004) 1.24
Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One (2008) 1.22
Multiplex detection of breast cancer biomarkers using plasmonic molecular sentinel nanoprobes. Nanotechnology (2009) 1.21
Targeting cancer-initiating cells with oncolytic viruses. Mol Ther (2009) 1.18
Cancer stem cells: how can we target them? Curr Med Chem (2008) 1.17
Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev (2009) 1.17
The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res (2009) 1.16
Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model. PLoS One (2009) 1.09
Recurrence cancer stem cells--made by cell fusion? Med Hypotheses (2009) 1.05
Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther (2006) 1.05
Vitamin D and differentiation in cancer. Crit Rev Clin Lab Sci (2009) 1.05
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res (2008) 1.05
Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer (2009) 1.03
Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res (2009) 1.00
Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol (2009) 0.99
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer (2008) 0.98
A Sweet-like syndrome manifesting as gingival hyperplasia and myositis without cutaneous involvement. Ann Hematol (2002) 0.97
Multipotent, dedifferentiated cancer stem-like cells from brain gliomas. Stem Cells Dev (2006) 0.96
Reovirus: Rationale and clinical trial update. Curr Opin Mol Ther (2009) 0.96
Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model. Biochem Pharmacol (2004) 0.95
Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression. BMC Cancer (2009) 0.94
Oncolytic adenoviruses targeted to cancer stem cells. Mol Cancer Ther (2009) 0.94
TGF-beta1 slows the growth of pathogenic myofibroblasts through a mechanism requiring the focal adhesion protein, Hic-5. J Invest Dermatol (2007) 0.93
Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells. Mol Pharm (2009) 0.91
The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell Microbiol (2009) 0.89
Oncolytic viral therapy using reovirus. Methods Mol Biol (2009) 0.89
Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Hum Pathol (2009) 0.88
Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine. Biochem Pharmacol (2009) 0.88